WO1998029445A1 - DERIVES α-AMINO-BUTYRATE DES VENINS - Google Patents
DERIVES α-AMINO-BUTYRATE DES VENINS Download PDFInfo
- Publication number
- WO1998029445A1 WO1998029445A1 PCT/EP1997/007333 EP9707333W WO9829445A1 WO 1998029445 A1 WO1998029445 A1 WO 1998029445A1 EP 9707333 W EP9707333 W EP 9707333W WO 9829445 A1 WO9829445 A1 WO 9829445A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- abu
- peptide
- homologous
- venom
- amino
- Prior art date
Links
- 231100000611 venom Toxicity 0.000 title claims abstract description 19
- 239000002435 venom Substances 0.000 title claims abstract description 18
- 210000001048 venom Anatomy 0.000 title claims abstract description 18
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical class CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 title description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 32
- 241001465754 Metazoa Species 0.000 claims abstract description 8
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 6
- 230000000890 antigenic effect Effects 0.000 claims abstract description 5
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 5
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims abstract description 4
- 229960005486 vaccine Drugs 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 101000654311 Androctonus australis Alpha-mammal toxin AaH2 Proteins 0.000 claims description 7
- 241000239226 Scorpiones Species 0.000 claims description 6
- 241001219494 Androctonus australis hector Species 0.000 claims description 4
- 241000239239 Androctonus Species 0.000 claims description 3
- 101000583076 Anemonia sulcata Delta-actitoxin-Avd1c Proteins 0.000 claims description 2
- 101000761697 Hemachatus haemachatus Short neurotoxin 1 Proteins 0.000 claims description 2
- 101000588937 Heteractis magnifica Delta-stichotoxin-Rpa1a Proteins 0.000 claims description 2
- 101000800755 Naja oxiana Alpha-elapitoxin-Nno2a Proteins 0.000 claims description 2
- 101000640206 Tityus serrulatus Alpha-mammal toxin Ts2 Proteins 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002581 neurotoxin Substances 0.000 claims description 2
- 231100000618 neurotoxin Toxicity 0.000 claims description 2
- 239000003123 plant toxin Substances 0.000 claims description 2
- 101710138657 Neurotoxin Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002795 scorpion venom Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 3
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical group CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 abstract description 2
- 231100000765 toxin Toxicity 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000003053 toxin Substances 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 239000003948 anatoxin Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 231100000740 envenomation Toxicity 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 238000002333 serotherapy Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- DOFAQXCYFQKSHT-SRVKXCTJSA-N Val-Pro-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DOFAQXCYFQKSHT-SRVKXCTJSA-N 0.000 description 2
- 230000001147 anti-toxic effect Effects 0.000 description 2
- 108010047857 aspartylglycine Proteins 0.000 description 2
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
- SGNXVBOIDPPRJJ-PSASIEDQSA-N 1-[(1r,6r)-9-azabicyclo[4.2.1]non-4-en-5-yl]ethanone Chemical compound CC(=O)C1=CCC[C@@H]2CC[C@H]1N2 SGNXVBOIDPPRJJ-PSASIEDQSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- DDBMKOCQWNFDBH-RHYQMDGZSA-N Arg-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O DDBMKOCQWNFDBH-RHYQMDGZSA-N 0.000 description 1
- BZMWJLLUAKSIMH-FXQIFTODSA-N Asn-Glu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BZMWJLLUAKSIMH-FXQIFTODSA-N 0.000 description 1
- GHWWTICYPDKPTE-NGZCFLSTSA-N Asn-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N GHWWTICYPDKPTE-NGZCFLSTSA-N 0.000 description 1
- QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 description 1
- YRBGRUOSJROZEI-NHCYSSNCSA-N Asp-His-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(O)=O YRBGRUOSJROZEI-NHCYSSNCSA-N 0.000 description 1
- 241000239311 Buthus Species 0.000 description 1
- 241000239327 Centruroides Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- XUDLUKYPXQDCRX-BQBZGAKWSA-N Gly-Arg-Asn Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O XUDLUKYPXQDCRX-BQBZGAKWSA-N 0.000 description 1
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 1
- NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- BMVFXOQHDQZAQU-DCAQKATOSA-N Leu-Pro-Asp Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N BMVFXOQHDQZAQU-DCAQKATOSA-N 0.000 description 1
- GQUDMNDPQTXZRV-DCAQKATOSA-N Lys-Arg-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O GQUDMNDPQTXZRV-DCAQKATOSA-N 0.000 description 1
- CIOWSLJGLSUOME-BQBZGAKWSA-N Lys-Asp Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O CIOWSLJGLSUOME-BQBZGAKWSA-N 0.000 description 1
- KWUKZRFFKPLUPE-HJGDQZAQSA-N Lys-Asp-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWUKZRFFKPLUPE-HJGDQZAQSA-N 0.000 description 1
- LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 description 1
- YPLVCBKEPJPBDQ-MELADBBJSA-N Lys-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N YPLVCBKEPJPBDQ-MELADBBJSA-N 0.000 description 1
- RIJCHEVHFWMDKD-SRVKXCTJSA-N Lys-Lys-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O RIJCHEVHFWMDKD-SRVKXCTJSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- LZHHZYDPMZEMRX-STQMWFEESA-N Pro-Tyr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O LZHHZYDPMZEMRX-STQMWFEESA-N 0.000 description 1
- QFBNNYNWKYKVJO-DCAQKATOSA-N Ser-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N QFBNNYNWKYKVJO-DCAQKATOSA-N 0.000 description 1
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 1
- UPLYXVPQLJVWMM-KKUMJFAQSA-N Ser-Phe-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UPLYXVPQLJVWMM-KKUMJFAQSA-N 0.000 description 1
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 1
- XVHAUVJXBFGUPC-RPTUDFQQSA-N Thr-Tyr-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O XVHAUVJXBFGUPC-RPTUDFQQSA-N 0.000 description 1
- 241000239273 Tityus Species 0.000 description 1
- AVYVKJMBNLPWRX-WFBYXXMGSA-N Trp-Ala-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 AVYVKJMBNLPWRX-WFBYXXMGSA-N 0.000 description 1
- HZYOWMGWKKRMBZ-BYULHYEWSA-N Val-Asp-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HZYOWMGWKKRMBZ-BYULHYEWSA-N 0.000 description 1
- KTEZUXISLQTDDQ-NHCYSSNCSA-N Val-Lys-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N KTEZUXISLQTDDQ-NHCYSSNCSA-N 0.000 description 1
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 1
- JPBGMZDTPVGGMQ-ULQDDVLXSA-N Val-Tyr-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N JPBGMZDTPVGGMQ-ULQDDVLXSA-N 0.000 description 1
- PMKQKNBISAOSRI-XHSDSOJGSA-N Val-Tyr-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N PMKQKNBISAOSRI-XHSDSOJGSA-N 0.000 description 1
- 101710099833 Venom protein Proteins 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002303 anti-venom Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 108010064486 phenylalanyl-leucyl-valine Proteins 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the invention relates to synthetic peptides which have amino acid sequences derived from naturally occurring animal or plant venoms but which incorporate ⁇ -amino-butyric acid residues, and to preparations containing the said synthetic peptides.
- Such synthetic peptides may have prophylactic and therapeutic uses, and these uses are included within the scope of the invention.
- Toxin inoculation essentially neurotropic, is responsible for envenomation which exerts a neurotoxic activity altering the action potential of nerves and muscles.
- Scorpions toxic to human beings and other mammals, are essentially represented by the following four species: Androctonus, Buthus, Tityus and Centruroides . Every year, world wide, there are approximately 150,000 incidences of human beings being stung by scorpions. 1,200 of these result in fatalities. In North Africa, scorpions of the species Androctonus are responsible for 80% of the incidences and 95% of the deaths.
- the scorpion neurotoxins which are lethal to mammals are basic peptides made up from 60 to 70 amino acid residues cross-linked by four disulphide bridges. Their target is the sodium potential depending channel of excitable cell membranes. There is a structural homology in toxins which determines a protein with specificities. However there is an antigenic polymorphism mainly among the proteins of this family.
- Classic treatment of envenomation is based on a poly specific serotherapy, the specific antibodies of which are obtained by a mixture of appropriate venoms of several scorpion species living in the same geographic area.
- a venom fraction enriched with toxins can be used in order to improve this serotherapy.
- this serotherapy is limited, because the toxins are so effective that the neutralising levels are low and the serum volume which must be administered is high.
- This serum antivenom usually of horse origin, is sometimes responsible for severe and even lethal anaphy lactic shocks.
- the invention provides a synthetic peptide having an amino acid sequence homologous or substantially homologous to that of a naturally occurring peptide animal or plant venom or to an active part thereof save that each cystine residue present in the venom or the active part thereof has been replaced in the synthetic peptide by two o.-amino-butyric acid residues, the synthetic peptide being non-toxic but retaining the antigenic properties of the venom.
- the synthetic peptides obtained can thus be used to raise specific sera in animals without adverse effects, and also to counteract recent envenomation by administration of non-toxic competitive agents.
- the invention thus opens routes to vaccines against animal or plant venoms, and treatments for those persons already envenomated.
- the Boc/benzyl strategy was used, including a systematic double coupling scheme with hydroxybenzotriazole active esters (Boc-AA-OBt).
- Final cleavage from the resin was effected with anhydrous hydrogen fluoride (1 hour at 0°C).
- the peptides were washed with diethyl ether and solubilised in water.
- the synthetic anatoxins were characterised by reverse phase analytical high pressure liquid chromatography (C18), the analysis of amino acids being performed after acid hydrolysis (6N hydrochloric acid, 115°C, 24 hours) and circular dichroism.
- 8(Abu)-AaH I contained 63 amino acid residues, its primary structure being KRDGYIVYPNN(Abu)VYH(Abu)VPP(Abu)DGL(Abu)KKNGGSSGS(Abu)SFLVPSGLA(A bu)W(Abu)KDLPDNVPIKDTSRK(Abu)T (SEQ ID NO. 1).
- 8(Abu)-AaH II contained 63 amino acid residues, its primary structure being VKDGYIVDDVN(Abu)TYF(Abu)GRNAY(Abu)NEE(Abu)TKLKGESGY(Abu)QWASPYG NA(Abu)Y(Abu)KLPDHVRTKGPGR(Abu)H-NH 2 (SEQ ID NO. 2).
- the synthetic anatoxins 8(Abu)-AaH I and 8(Abu)-AaH II were injected into mice by the intracerebro ventricular route at doses of 200 ⁇ g. No toxic effects were observed. Repeated subcutaneous injections of 8(Abu)-AaH II did not elicit any sign of toxicity in mice.
- mice were injected with 8(Abu)-AaH II.
- the mice were subcutaneously injected with five times the LD 50 of the natural toxin AaH II. No symptoms of toxicity were observed.
- the mice were again injected subcutaneously with the natural toxin AaH II, this time in the amount of twelve times the LD 50 . Again the treated animals did not present any clinical or biological sign of toxicity.
- the animals were thus immunised against Androctonus australis Hector (AaH II) natural toxin.
- the Abu peptides according to the invention retain the antigenic properties of the natural toxins but do not present the neurotoxic properties observed with the natural venom proteins.
- Lys Arg Asp Gly Tyr lie Val Tyr Pro Asn Asn Xaa Val Tyr His Xaa 1 5 10 15
- Val Lys Asp Gly Tyr lie Val Asp Asp Val Asn Xaa Thr Tyr Phe Xaa 1 5 10 15
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Insects & Arthropods (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des peptides de synthèse présentant des séquences d'acides aminés homologues ou sensiblement homologues à ceux se trouvant naturellement dans les venins de plantes ou d'animaux, à la différence que chaque résidu de cystine présent dans le venin a été remplacé dans le peptide de synthèse par deux résidus d'acide α-amino-butyriques. Les peptides de synthèse sont non toxiques mais conservent les propriétés antigéniques du venin. Ils peuvent, par conséquent, être utilisés pour préparer des vaccins contre le venin, et également traiter des personnes déjà envenimées.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9915067A GB2335923B (en) | 1996-12-31 | 1997-12-30 | Amino-butyrate derivatives of venoms |
AU58611/98A AU5861198A (en) | 1996-12-31 | 1997-12-30 | Alpha-amino-butyrate derivatives of venoms |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9627115.0A GB9627115D0 (en) | 1996-12-31 | 1996-12-31 | Alpha-amino-butyrate derivatives of venoms |
GB9627115.0 | 1996-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998029445A1 true WO1998029445A1 (fr) | 1998-07-09 |
Family
ID=10805140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/007333 WO1998029445A1 (fr) | 1996-12-31 | 1997-12-30 | DERIVES α-AMINO-BUTYRATE DES VENINS |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU5861198A (fr) |
GB (2) | GB9627115D0 (fr) |
WO (1) | WO1998029445A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002020596A2 (fr) * | 2000-09-04 | 2002-03-14 | Cellpep S.A. | Maurotoxine, derives pi1 et hstx1 |
-
1996
- 1996-12-31 GB GBGB9627115.0A patent/GB9627115D0/en active Pending
-
1997
- 1997-12-30 AU AU58611/98A patent/AU5861198A/en not_active Abandoned
- 1997-12-30 GB GB9915067A patent/GB2335923B/en not_active Expired - Lifetime
- 1997-12-30 WO PCT/EP1997/007333 patent/WO1998029445A1/fr active Application Filing
Non-Patent Citations (4)
Title |
---|
CHAVEZ-OLORTEGUI E.A.: "In vivo protection against scorpion toxins by liposomal immunization", VACCINE., vol. 9, no. 12, December 1991 (1991-12-01), GUILDFORD GB, pages 907 - 910, XP002064838 * |
SABATIER E.A.: "Synthesis and characterization of leiurotoxin I lacking one disulfide bridge", BIOCHEMISTRY, vol. 35, no. 33, 20 August 1996 (1996-08-20), EASTON, PA US, pages 10641 - 10647, XP002064839 * |
XU E.A.: "One-disulfide intermediates of apamin exhibit native-like structure", BIOCHEMISTRY, vol. 33, no. 17, 1994, EASTON, PA US, pages 5253 - 5261, XP002064840 * |
ZENOUAKI E.A.: "In vivo protection against Androctonus australis hector scorpion toxin and venom by immunization with a synthetic analog of toxin II", VACCINE., vol. 15, no. 2, February 1997 (1997-02-01), GUILDFORD GB, pages 187 - 194, XP004054370 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002020596A2 (fr) * | 2000-09-04 | 2002-03-14 | Cellpep S.A. | Maurotoxine, derives pi1 et hstx1 |
WO2002020596A3 (fr) * | 2000-09-04 | 2002-08-01 | Cellpep Sa | Maurotoxine, derives pi1 et hstx1 |
US7829666B2 (en) | 2000-09-04 | 2010-11-09 | Cellpep Pharma Inc. | Maurotoxin, PI1 and HSTX1 derivatives |
Also Published As
Publication number | Publication date |
---|---|
GB2335923B (en) | 2001-03-14 |
GB2335923A (en) | 1999-10-06 |
AU5861198A (en) | 1998-07-31 |
GB9915067D0 (en) | 1999-08-25 |
GB9627115D0 (en) | 1997-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5464823A (en) | Mammalian antibiotic peptides | |
Misono et al. | Rat atrial natriuretic factor: isolation, structure and biological activities of four major peptides | |
USRE39240E1 (en) | Conotoxins I | |
Sabatier et al. | P05, a new leiurotoxin I-like scorpion toxin: Synthesis and structure-activity relationships of the. alpha.-amidated analog, a ligand of calcium-activated potassium channels with increased affinity | |
US6197926B1 (en) | Methods for treatment of diabetes using peptide analogues of insulin | |
US7666840B2 (en) | α-Conotoxin peptides | |
Bouhaouala‐Zahar et al. | A recombinant insect‐specific α‐toxin of Buthus occitanus tunetanus scorpion confers protection against homologous mammal toxins | |
Hashim et al. | Definition and synthesis of the essential amino acid sequence for experimental allergic encephalomyelitis in Lewis rats | |
CA2247328C (fr) | Neuropeptides provenant du scorpion | |
US5776758A (en) | Cysteine protease derived from parasitic helminths | |
US5866682A (en) | Conopeptides AuIA, AuIB and AuIC | |
WO1998029445A1 (fr) | DERIVES α-AMINO-BUTYRATE DES VENINS | |
AU770076B2 (en) | Alpha-conotoxin peptides | |
US7390785B2 (en) | τ-conotoxin peptides | |
Westall et al. | Encephalitogenic regions for the Lewis rat within the myelin basic protein | |
AU707483B2 (en) | Peptides for anti-allergy treatment | |
JP3776968B2 (ja) | ペプチド性サソリ毒素 | |
CA2145960A1 (fr) | Proteine phbp-70 | |
JPH09278797A (ja) | サソリ毒素関連ペプチド | |
CA1340077C (fr) | Derives ¬ser 17, leu 18| grf | |
WO2006098764A2 (fr) | Bloqueurs de canaux potassiques | |
EP1852440A1 (fr) | Peptides alpha-conotoxines | |
LUCAS et al. | SCORPION Tityus serrulatus LUTZ AND MELLO. | |
KRUGGEL | A Complete Amino Acid Sequence for the Basic Subunit of Crotoxin | |
WO1996030405A1 (fr) | Peptides avec des proprietes favorisant la croissance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |